^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Serous Adenocarcinoma

    Related cancers:
    3d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    9d
    MicroRNA Signatures in Serous Ovarian Cancer: A Comparison of Prognostic Marker Targets in African Americans and Caucasians. (PubMed, Diseases)
    Pathway enrichment and gene ontology analyses (miRTargetLink2.0, Enrichr) revealed interconnected regulatory networks linking miR-192, miR-16-5p, miR-143-3p, and miR-20a-5p to ITGB1; miR-143-3p/miR-145-5p to BRAF; and miR-16-5p and miR-30c/d to TIMP3. Collectively, these findings identify distinct miRNA-mRNA regulatory signatures-particularly the miR-192-5p-ITGB1/TIMP3 axis-as potential clinically relevant biomarkers that may contribute to racial disparities and disease progression in ovarian cancer.
    Journal
    |
    BRAF (B-raf proto-oncogene) • MIR192 (MicroRNA 192) • MIR143 (MicroRNA 143) • MIR16 (MicroRNA 16) • MIR30D (MicroRNA 30d) • ITGB1 (Integrin Subunit Beta 1) • MIR145 (MicroRNA 145) • MIR20A (MicroRNA 20a) • MIR30C • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    10d
    Mechanistic insights into c-Met rs368750834 mutation and a bifunctional CAR-T strategy for serous ovarian carcinoma. (PubMed, J Ovarian Res)
    These cells exhibited markedly enhanced cytotoxicity against tumour cells overexpressing c-Met, accompanied by increased release of key effector cytokines such as interferon-γ. This research framework offers a precise, synergistic therapeutic strategy to overcome limitations in CAR-T therapy response within serous ovarian carcinoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • IFNG (Interferon, gamma)
    |
    MET overexpression • MET mutation
    11d
    Mutant p53 Disrupts Antioxidant Defense in Fallopian Tube Epithelium via GSTAs Suppression: A Pathway to Serous Tubal Carcinogenesis. (PubMed, Free Radic Biol Med)
    Mutant p53 downregulated the expression of GSTA2 and subsequently increased DNA damage. The combination of p53 mutation and dysregulated oxidative response likely promotes the genomic instability that initially drives the transformation to high grade serous ovarian carcinoma.
    Journal
    |
    TP53 (Tumor protein P53) • GSTA2 (Glutathione S-Transferase Alpha 2)
    |
    TP53 mutation
    13d
    First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. (PubMed, ESMO Open)
    MSLN-TTC showed good tolerability, but the maximum tolerated dose could not be determined due to discontinuations after antidrug antibody formation. Stable disease was observed in 12 out of 36 patients.
    P1 data • Journal • First-in-human
    |
    MSLN (Mesothelin)
    |
    thorium (227Th) anetumab corixetan (BAY 2287411)
    16d
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Sep 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    18d
    DIRAS3-derived cyclic peptides disrupt KRAS-RAF interaction and KRAS nanoclustering, suppressing KRAS-driven pancreatic and ovarian tumors. (PubMed, iScience)
    Functionally, they reduce cell viability and suppress PDAC and LGSOC growth in cell culture and xenograft models. Our findings demonstrate that DIRAS3-based cyclic peptides represent a distinct strategy to directly inhibit oncogenic KRAS signaling and provide a promising framework for therapeutic development in KRAS-driven cancers.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • DIRAS3 (DIRAS Family GTPase 3)
    |
    KRAS mutation
    21d
    Incidentally Discovered Ovarian Cancer Combined With Obturator Nerve Schwannoma: A Rare Case Report. (PubMed, Clin Case Rep)
    After three cycles of paclitaxel-carboplatin, the ovarian disease regressed while the sidewall mass was unchanged. Posttreatment CT met the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for complete response; the patient received maintenance olaparib plus bevacizumab and, at 32-month follow-up, had no evidence of recurrence with intact adductor function. This case suggests that, during ovarian cancer cytoreduction, a stable, well-circumscribed sidewall mass on CT-particularly along the obturator canal-should raise suspicion for a neurogenic tumor; when biopsy access is unsafe and open surgery is planned, nerve-sparing enucleation is an appropriate management option.
    Journal • PARP Biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel
    21d
    Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov)
    P2/3, N=260, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate)
    27d
    Drug target proteome profiling identifies HES1-driven mitotic catastrophe in ovarian serous carcinoma. (PubMed, Biomed Pharmacother)
    Cell-cycle analyses confirm enhanced DNA damage response and G2/M arrest when combined with olaparib. These findings uncover a novel mechanism for BX-912, establish HES1 inhibition as a therapeutic strategy in HGSC, demonstrate proteomics' power to reveal hidden drug activities, and propose sequential cell-cycle targeting to improve treatment efficacy.
    Journal
    |
    BRCA (Breast cancer early onset) • HES1 (Hes Family BHLH Transcription Factor 1) • PDPK1 (3-Phosphoinositide dependent protein kinase 1)
    |
    Lynparza (olaparib)
    29d
    Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine. (PubMed, Future Oncol)
    Notably, the recent US Food and Drug Administration approval of the avutometinib/defactinib combination for KRAS-mutated recurrent LGSOC marks a significant milestone in targeted therapy for this disease. Despite these advances, challenges remain in optimizing sequencing strategies and overcoming acquired resistance. This review addresses the importance of understanding the distinct pathophysiology of LGSOC, diagnostic challenges, limitations of conventional treatments, and evolving therapeutic approaches in LGSOC.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    1m
    Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms (PARAGON-II) (ACTRN12621000639820)
    P2, N=182, Active, not recruiting, The University of Sydney | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HR positive